Journal of Clinical Oncology, Vol 18, Issue 8
(April), 2000: 1622-1636
© 2000 American Society for Clinical Oncology
Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies
By Robert J. Kreitman,
Wyndham H. Wilson,
Jeffrey D. White,
Maryalice Stetler-Stevenson,
Elaine S. Jaffe,
Steven Giardina,
Thomas A. Waldmann,
Ira Pastan
From the Laboratories of Molecular BiologyLaboratory of Clinical Pathology, Metabolism Branch, Medicine Branch, and Biopharmaceutical Development Program, Science Applications International Corporation Frederick, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Address reprint requests to Ira Pastan, MD, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Building 37/4E16, 9000 Rockville Pike, Bethesda, MD 20892.
PURPOSE: To evaluate the toxicity, pharmacokinetics, immunogenicity, and antitumor activity of anti-Tac(Fv)-PE38 (LMB-2), an anti-CD25 recombinant immunotoxin that contains an antibody Fv fragment fused to truncated Pseudomonas exotoxin.
PATIENTS AND METHODS: Patients with CD25+ hematologic malignancies for whom standard and salvage therapies failed were treated with LMB-2 at dose levels that ranged from 2 to 63 µg/kg administered intravenously over 30 minutes on alternate days for three doses (QOD x 3).
RESULTS: LMB-2 was administered to 35 patients for a total of 59 cycles. Dose-limiting toxicity at the 63 µg/kg level was reversible and included transaminase elevations in one patient and diarrhea and cardiomyopathy in another. LMB-2 was well tolerated in nine patients at the maximum-tolerated dose (40 µg/kg QOD x 3); toxicity was transient and most commonly included transaminase elevations (eight patients) and fever (seven patients). Only six of 35 patients developed significant neutralizing antibodies after the first cycle. The median half-life was 4 hours. One hairy cell leukemia (HCL) patient achieved a complete remission, which is ongoing at 20 months. Seven partial responses were observed in cutaneous T-cell lymphoma (one patient), HCL (three patients), chronic lymphocytic leukemia (one patient), Hodgkin’s disease (one patient), and adult T-cell leukemia (one patient). Responding patients had 2 to 5 log reductions of circulating malignant cells, improvement in skin lesions, and regression of lymphomatous masses and splenomegaly. All four patients with HCL responded to treatment.
CONCLUSION: LMB-2 has clinical activity in CD25+ hematologic malignancies and is relatively nonimmunogenic. It is the first recombinant immunotoxin to induce major responses in cancer. LMB-2 and similar agents that target other cancer antigens merit further clinical development.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
H. M. Prince, S. Whittaker, and R. T. Hoppe
How I treat mycosis fungoides and Sezary syndrome
Blood,
November 12, 2009;
114(20):
4337 - 4353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Mahmud, B. Dalken, and W. S. Wels
Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor
Mol. Cancer Ther.,
June 1, 2009;
8(6):
1526 - 1535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Weldon, L. Xiang, O. Chertov, I. Margulies, R. J. Kreitman, D. J. FitzGerald, and I. Pastan
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
Blood,
April 16, 2009;
113(16):
3792 - 3800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lupinek, K. H. Roux, S. Laffer, I. Rauter, K. Reginald, M. Kneidinger, K. Blatt, T. Ball, I. Pree, B. Jahn-Schmid, et al.
Trimolecular Complex Formation of IgE, Fc{epsilon}RI, and a Recombinant Nonanaphylactic Single-Chain Antibody Fragment with High Affinity for IgE
J. Immunol.,
April 15, 2009;
182(8):
4817 - 4829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Onda, R. Beers, L. Xiang, S. Nagata, Q.-c. Wang, and I. Pastan
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes
PNAS,
August 12, 2008;
105(32):
11311 - 11316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Sampson, G. Akabani, G. E. Archer, M. S. Berger, R. E. Coleman, A. H. Friedman, H. S. Friedman, K. Greer, J. E. Herndon II, S. Kunwar, et al.
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
Neuro-oncol,
January 1, 2008;
10(3):
320 - 329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Du, S. Nagata, T. Ise, M. Stetler-Stevenson, and I. Pastan
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins
Blood,
January 1, 2008;
111(1):
338 - 343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Powell Jr., A. Felipe-Silva, M. J. Merino, M. Ahmadzadeh, T. Allen, C. Levy, D. E. White, S. Mavroukakis, R. J. Kreitman, S. A. Rosenberg, et al.
Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo
J. Immunol.,
October 1, 2007;
179(7):
4919 - 4928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hassan, S. Bullock, A. Premkumar, R. J. Kreitman, H. Kindler, M. C. Willingham, and I. Pastan
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers
Clin. Cancer Res.,
September 1, 2007;
13(17):
5144 - 5149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Singh, L. M. Serrano, T. Pfeiffer, S. Olivares, G. McNamara, D. D. Smith, Z. Al-Kadhimi, S. J. Forman, S. D. Gillies, M. C. Jensen, et al.
Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy
Cancer Res.,
March 15, 2007;
67(6):
2872 - 2880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Onda, S. Nagata, D. J. FitzGerald, R. Beers, R. J. Fisher, J. J. Vincent, B. Lee, M. Nakamura, J. Hwang, R. J. Kreitman, et al.
Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients
J. Immunol.,
December 15, 2006;
177(12):
8822 - 8834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Kennedy, T. K. Bera, Q.-C. Wang, M. Gallo, W. Wagner, M. G. Lewis, E. A. Berger, and I. Pastan
Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques
J. Leukoc. Biol.,
November 1, 2006;
80(5):
1175 - 1182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zhang, L. Xiang, R. Hassan, C. H. Paik, J. A. Carrasquillo, B.-s. Jang, N. Le, M. Ho, and I. Pastan
Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice
Clin. Cancer Res.,
August 1, 2006;
12(15):
4695 - 4701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nagata, T. Ise, M. Onda, K. Nakamura, M. Ho, A. Raubitschek, and I. H. Pastan
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy
PNAS,
May 31, 2005;
102(22):
7946 - 7951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Matsusaka, J. Xin, S. Niwa, K. Kobayashi, A. Akatsuka, H. Hashizume, Q.-c. Wang, I. Pastan, A. B. Fogo, and I. Ichikawa
Genetic Engineering of Glomerular Sclerosis in the Mouse via Control of Onset and Severity of Podocyte-Specific Injury
J. Am. Soc. Nephrol.,
April 1, 2005;
16(4):
1013 - 1023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Sampson, D. A. Reardon, A. H. Friedman, H. S. Friedman, R. E. Coleman, R. E. McLendon, I. Pastan, and D. D. Bigner
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study
Neuro-oncol,
January 1, 2005;
7(1):
90 - 96.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Ise, H. Maeda, K. Santora, L. Xiang, R. J. Kreitman, I. Pastan, and S. Nagata
Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies
Clin. Cancer Res.,
January 1, 2005;
11(1):
87 - 96.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ishida, S. Iida, Y. Akatsuka, T. Ishii, M. Miyazaki, H. Komatsu, H. Inagaki, N. Okada, T. Fujita, K. Shitara, et al.
The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/Lymphoma
Clin. Cancer Res.,
November 15, 2004;
10(22):
7529 - 7539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Decker, M. Oelsner, R. J. Kreitman, G. Salvatore, Q.-c. Wang, I. Pastan, C. Peschel, and T. Licht
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins
Blood,
April 1, 2004;
103(7):
2718 - 2726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Onda, Q.-c. Wang, H.-f. Guo, N.-K. V. Cheung, and I. Pastan
In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma
Cancer Res.,
February 15, 2004;
64(4):
1419 - 1424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Di Paolo, J. Willuda, S. Kubetzko, I. Lauffer, D. Tschudi, R. Waibel, A. Pluckthun, R. A. Stahel, and U. Zangemeister-Wittke
A Recombinant Immunotoxin Derived from a Humanized Epithelial Cell Adhesion Molecule-specific Single-Chain Antibody Fragment Has Potent and Selective Antitumor Activity
Clin. Cancer Res.,
July 1, 2003;
9(7):
2837 - 2848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Schnell, P. Borchmann, J. O. Staak, J. Schindler, V. Ghetie, E. S. Vitetta, and A. Engert
Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma
Ann. Onc.,
May 1, 2003;
14(5):
729 - 736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.C. Church
Clinical advances in therapies targeting the interleukin-2 receptor
QJM,
February 1, 2003;
96(2):
91 - 102.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. McHugh, S. Hu, B. K. Lee, K. Santora, P. E. Kennedy, E. A. Berger, I. Pastan, and D. H. Hamer
Increased Affinity and Stability of an Anti-HIV-1 Envelope Immunotoxin by Structure-based Mutagenesis
J. Biol. Chem.,
September 6, 2002;
277(37):
34383 - 34390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nagata, M. Onda, Y. Numata, K. Santora, R. Beers, R. J. Kreitman, and I. Pastan
Novel Anti-CD30 Recombinant Immunotoxins Containing Disulfide-stabilized Fv Fragments
Clin. Cancer Res.,
July 1, 2002;
8(7):
2345 - 2355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Fan, S. Yano, H. Shinohara, C. Solorzano, M. Van Arsdall, C. D. Bucana, S. Pathak, E. Kruzel, R. S. Herbst, A. Onn, et al.
Targeted Therapy against Human Lung Cancer in Nude Mice by High-Affinity Recombinant Antimesothelin Single-Chain Fv Immunotoxin
Mol. Cancer Ther.,
June 1, 2002;
1(8):
595 - 600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Schnell, O. Staak, P. Borchmann, C. Schwartz, B. Matthey, H. Hansen, J. Schindler, V. Ghetie, E. S. Vitetta, V. Diehl, et al.
A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30+ Hodgkin's and Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
June 1, 2002;
8(6):
1779 - 1786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Peipp, H. Kupers, D. Saul, B. Schlierf, J. Greil, S. J. Zunino, M. Gramatzki, and G. H. Fey
A Recombinant CD7-specific Single-Chain Immunotoxin Is a Potent Inducer of Apoptosis in Acute Leukemic T Cells
Cancer Res.,
May 1, 2002;
62(10):
2848 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Frankel, B. L. Powell, P. D. Hall, L. D. Case, and R. J. Kreitman
Phase I Trial of a Novel Diphtheria Toxin/Granulocyte Macrophage Colony-stimulating Factor Fusion Protein (DT388GMCSF) for Refractory or Relapsed Acute Myeloid Leukemia
Clin. Cancer Res.,
May 1, 2002;
8(5):
1004 - 1013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Rajvanshi, H. M. Shulman, E. L. Sievers, and G. B. McDonald
Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy
Blood,
April 1, 2002;
99(7):
2310 - 2314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Decker, S. Hipp, R. J. Kreitman, I. Pastan, C. Peschel, and T. Licht
Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides
Blood,
February 15, 2002;
99(4):
1320 - 1326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Connors, E. D. Hsi, and F. M. Foss
Lymphoma of the Skin
Hematology,
January 1, 2002;
2002(1):
263 - 282.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Huhn, S. Sasse, M. K. Tur, B. Matthey, T. Schinkothe, S. M. Rybak, S. Barth, and A. Engert
Human Angiogenin Fused to Human CD30 Ligand (Ang-CD30L) Exhibits Specific Cytotoxicity against CD30-positive Lymphoma
Cancer Res.,
December 1, 2001;
61(24):
8737 - 8742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Kreitman, W. H. Wilson, K. Bergeron, M. Raggio, M. Stetler-Stevenson, D. J. FitzGerald, and I. Pastan
Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia
N. Engl. J. Med.,
July 26, 2001;
345(4):
241 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Onda, S. Nagata, Y. Tsutsumi, J. J. Vincent, Q.-c. Wang, R. J. Kreitman, B. Lee, and I. Pastan
Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity
Cancer Res.,
July 1, 2001;
61(13):
5070 - 5077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Onda, M. Willingham, Q.-c. Wang, R. J. Kreitman, Y. Tsutsumi, S. Nagata, and I. Pastan
Inhibition of TNF-{alpha} Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2
J. Immunol.,
December 15, 2000;
165(12):
7150 - 7156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Vickers and P. Christos
Re: "Bezwoda: evidence of fabrication in original article".
J. Clin. Oncol.,
November 15, 2000;
18(22):
3875 - 3875.
[Full Text]
|
|
|
|
|
|
|
J. C Morris and T. A Waldmann
Advances in interleukin 2 receptor targeted treatment
Ann Rheum Dis,
November 1, 2000;
59(90001):
i109 - 114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tsutsumi, M. Onda, S. Nagata, B. Lee, R. J. Kreitman, and I. Pastan
Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity
PNAS,
July 5, 2000;
(2000)
140210597.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Y. Tsutsumi, M. Onda, S. Nagata, B. Lee, R. J. Kreitman, and I. Pastan
Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity
PNAS,
July 18, 2000;
97(15):
8548 - 8553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
